Home » Posts tagged with » Massachusetts
Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J

Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J

J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion deal to acquire Momenta Pharmaceuticals, a biotech company based in Cambridge, Massachusetts, which is focused on developing drugs for the treatment of rare immune-mediated diseases. As per the terms of the all-cash transaction, shareholders of Momenta Pharmaceuticals […]

InnovHeart raises €20m for TMVR systems for mitral valve disease

InnovHeart, an Italian medical device manufacturer, has raised €20 million in a Series B funding round for its transcatheter mitral valve replacement systems (TMVR systems) for the treatment of mitral valve disease. Existing investor Genextra, which has been the lone investor in InnovHeart since its founding in 2015, took part in the funding round. A […]

Continue reading …
BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS

NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the dosing of all the participants in a phase 3 trial of NurOwn (MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The late-stage trial enrolled nearly 200 participants, who have been randomized […]

Continue reading …
Novo Nordisk to acquire cardio-renal disease company Corvidia Therapeutics

Novo Nordisk acquisition of Corvidia : Danish pharma company Novo Nordisk has agreed to acquire Corvidia Therapeutics from life sciences venture capital firm Sofinnova Partners in a deal worth up to $2.1 billion, in a move to expand its presence in cardiovascular disease. Corvidia Therapeutics, which is based in Boston, Massachusetts, was spun out from […]

Continue reading …
Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma

Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular lymphoma (FL). As per the new drug application (NDA) that has been accepted by the FDA, the Massachusetts-based biopharma company is seeking the accelerated approval of the methyltransferase inhibitor for […]

Continue reading …
Lyra Therapeutics raises $30m for chronic rhinosinusitis drug candidates

Lyra Therapeutics has raised $30 million in a Series C financing round to advance its lead product candidates for the treatment of chronic rhinosinusitis (CRS). Known as an inflammatory disease of the paranasal sinuses, chronic rhinosinusitis is said to affect around 14 million people in the US. The lead product candidates of the US-based clinical-stage […]

Continue reading …
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]

Continue reading …
Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy

Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene therapy for Duchenne muscular dystrophy (DMD). As per the agreement terms, Sarepta Therapeutics will get an upfront payment made up of $750 million in cash and $400 […]

Continue reading …
Glaukos closes Avedro acquisition to expand corneal health franchise

Glaukos acquisition of Avedro : Glaukos Corporation, a California-based ophthalmic medical technology and pharmaceutical company, has completed its previously announced acquisition of Avedro. Based in Waltham, Massachusetts, Avedro is a hybrid ophthalmic pharmaceutical and medical technology company, which is focused on treating corneal disease and disorders and enhancing vision to decrease dependency on eyeglasses or […]

Continue reading …
CD&R to acquire Cynosure medical aesthetics business from Hologic for $205m

Clayton, Dubilier & Rice (CD&R), a New York-based private equity firm, has signed an all-cash deal worth $205 million to acquire Cynosure, a medical aesthetics technology company, from US medical device company Hologic. Based in Massachusetts, Cynosure provides medical aesthetic treatment systems for plastic surgeons, dermatologists, medical spas and other healthcare practitioners. Cynosure’s product portfolio […]

Continue reading …
Page 1 of 3123